Phio Pharmaceuticals Corp. (PHIO)
Nasdaq: PHIO · Pharmaceutical Preparations · King Of Prussia, PA · filing with the SEC since 2011
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 5, 2026 | Mar 31, 2025 | Apr 1, 2024 | Mar 22, 2023 | Mar 22, 2022 | Mar 25, 2021 | Mar 26, 2020 | Mar 27, 2019 | Mar 26, 2018 | Mar 30, 2017 |
| Revenue | · | · | · | · | · | 0 | 21 | 138 | 15 | 19 |
| For lenders | ||||||||||
| Net interest income | · | 231 | -8 | · | · | · | · | · | · | · |
| Research and development | 4,618 | 3,643 | 6,332 | 7,012 | 8,886 | 3,716r | 4,300 | 4,326 | 5,370 | 5,415 |
| General and administrative | 4,602 | 3,744 | 4,366 | 4,450 | 4,625 | 5,077r | 4,708 | 3,176 | 4,011 | 3,619 |
| Total operating expenses | 9,220 | 7,387 | 10,824 | 11,462 | 13,511 | 8,793 | 9,008 | 7,502 | 14,077 | 9,034 |
| Operating income | -9,220 | -7,387 | -10,824 | -11,462 | -13,511 | -8,793 | -8,987 | -7,364 | -14,062 | -9,015 |
| Interest and investment income | 520 | 231 | · | · | · | · | · | · | · | · |
| Interest income (expense), net | · | · | · | · | -9 | -1 | · | · | -1 | 15 |
| Other income (expense), net | 2 | 6 | · | · | · | · | · | · | -10 | 6 |
| Total non-operating income (expense) | · | · | -2 | -18 | 224 | -1 | 79 | 4 | -11 | 21 |
| Income before income taxes | · | · | · | -11,480 | -13,287 | -8,794 | -8,908 | -7,360 | -14,073 | -8,994 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,621 | 0 |
| Net income | -8,698 | -7,150 | -10,826 | -11,480 | -13,287 | -8,794 | -8,908 | -7,360 | -12,452 | -8,994 |
| Preferred dividends | · | · | · | · | · | · | · | · | · | 2,075 |
| Net income to common shareholders | · | · | · | · | · | · | · | · | -12,452 | -11,069 |
| Earnings per share, basic | -1.45 | -9.08 | -46.76r | -90.90b | -111.87b | · | · | · | · | · |
| Earnings per share, diluted | · | -9.08 | -46.76r | -90.90b | -111.87b | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -9.36b | -17.28b | -173.97b | -517.14rb | -49.68b | -147.69rb |
| Weighted average shares, basic | 5,984,017 | 787,466 | 231,508r | 126,285b | 118,804b | · | · | · | · | · |
| Weighted average shares, diluted | · | 787,466 | 231,508r | 126,285b | 118,804b | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 1,425,645b | 509,705b | 51,201b | 14,232rb | 250,862b | 74,956rb |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-9 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesNet interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeNetInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted